Trafermin information

Trafermin
Clinical data
Trade names	Fiblast
Other names	CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
Routes of; administration	Topical (spray)
ATC code	D03AX15 (WHO) ;
Identifiers
CAS Number	131094-16-1;
PubChem SID	17397511;
ChemSpider	none;
UNII	333OX80X87;
KEGG	D03362;
Chemical and physical data
Formula	C764H1201N217O219S6
Molar mass	17122.67 g·mol−1

Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.^[2]^[3]^[1] It is also currently in preregistration for the treatment of periodontitis.^[2]^[4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.^[5]^[6] The drug has been marketed in Japan since June 2001.^{[citation needed]}

^ ^a ^b Han SK (15 September 2015). "Growth Factor Therapy". Innovations and Advances in Wound Healing. Springer. pp. 206–. ISBN 978-3-662-46587-5.
^ ^a ^b "Trafermin - Kaken Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
^ "Trafermin". Drugs.com.
^ Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, et al. (April 2016). "Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects". Journal of Bone and Mineral Research. 31 (4): 806–814. doi:10.1002/jbmr.2738. PMID 26547659.
^ Barnard JA, McHugh KM (10 May 2006). "Growth Factors in the Gastrointestinal Tract". In Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (eds.). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.
^ Hamid M. Said (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.

[Han2015-1] Han SK (15 September 2015). "Growth Factor Therapy". Innovations and Advances in Wound Healing. Springer. pp. 206–. ISBN 978-3-662-46587-5.

[AdisInsight-2] "Trafermin - Kaken Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.

[Drugs.com-3] "Trafermin". Drugs.com.

[pmid26547659-4] Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, et al. (April 2016). "Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects". Journal of Bone and Mineral Research. 31 (4): 806–814. doi:10.1002/jbmr.2738. PMID 26547659.

[BarrettGhishan2006-5] Barnard JA, McHugh KM (10 May 2006). "Growth Factors in the Gastrointestinal Tract". In Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (eds.). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.

[Said2012-6] Hamid M. Said (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.

Trafermin information

and 26 Related for: Trafermin information

Trafermin

Dexamethasone

Insulin

Erythropoietin

Testosterone

Amitriptyline

ATC code D03

Neurotrophic factors

Fruquintinib

Amivantamab

Faricimab

Nerve growth factor

Osimertinib

Tyrosine kinase inhibitor

Trastuzumab deruxtecan

Nintedanib

Epidermal growth factor

HER2

Growth factor

Bevacizumab

Cabozantinib

Wnt signaling pathway

Fibroblast growth factor

Dabrafenib

Alectinib

Encorafenib